×

Eli Lilly's CEO on Prescription for Profits

7:10 AM ET Wed, 25 April 2012

John Lechleiter, Eli Lilly chairman & CEO breaks down his company's earnings results of an adjusted $0.92 a share versus estimates of $0.78 est. and a look at the drug maker's generic challenges, and the politics of prescriptions.